CoChat

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Schalm, Stefanie S., O’Hearn, Erin, Wilson, Kevin, LaBranche, Timothy P., Silva, Grace, Zhang, Zhuo, DiPietro, Lucian, Bifulco, Neil, Woessner, Richard, Stransky, Nicolas, Sappal, Darshan, Campbell, Robert, Lobbardi, Riadh, Palmer, Michael, Kim, Joseph, Ye, Chaoyang, Dorsch, Marion, Lengauer, Christoph, Guzi, Timothy, Kadambi, Vivek, Garner, Andrew, Hoeflich, Klaus P. · 2023 · Gastro Hep Advances
Cited by 14

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gastha.2022.11.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 43

  1. Riggle, 2016, Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma, Pediatr Blood Cancer, 63, 1163, 10.1002/pbc.25970 · DOI · Paper page
  2. Eggert, 2013, Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database, United European Gastroenterol J, 1, 351, 10.1177/2050640613501507 · doi:10.1177/2050640613501507
  3. Ang, 2013, Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium, Gastrointest Cancer Res, 6, 3
  4. Kaseb, 2013, Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma, Oncology, 85, 197, 10.1159/000354698 · doi:10.1159/000354698
  5. Groeschl, 2014, Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma, J Surg Oncol, 110, 412, 10.1002/jso.23658 · doi:10.1002/jso.23658
  6. Stipa, 2006, Outcome of patients with fibrolamellar hepatocellular carcinoma, Cancer, 106, 1331, 10.1002/cncr.21703 · doi:10.1002/cncr.21703
  7. Chakrabarti, 2019, Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma, J Gastrointest Oncol, 10, 554, 10.21037/jgo.2019.01.35 · doi:10.21037/jgo.2019.01.35
  8. Ward, 2011, Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors, Semin Liver Dis, 31, 61, 10.1055/s-0031-1272835 · doi:10.1055/s-0031-1272835
  9. Ward, 2010, Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation, Mod Pathol, 23, 1180, 10.1038/modpathol.2010.105 · DOI
  10. Ross, 2011, Fibrolamellar carcinomas are positive for CD68, Mod Pathol, 24, 390, 10.1038/modpathol.2010.207 · doi:10.1038/modpathol.2010.207
  11. Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9 · DOI · Paper page
  12. Dinh, 2017, Comprehensive analysis of the Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma, Sci Rep, 7, 44653, 10.1038/srep44653 · DOI
  13. Simon, 2015, Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci U S A, 112, E5916, 10.1073/pnas.1424894112 · DOI · Paper page
  14. Honeyman, 2014, Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 · DOI · Paper page
  15. Cornella, 2015, Unique genomic profile of fibrolamellar hepatocellular carcinoma, Gastroenterology, 148, 806, 10.1053/j.gastro.2014.12.028 · DOI
  16. Engelholm, 2017, CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, 153, 1662, 10.1053/j.gastro.2017.09.008 · DOI
  17. Kastenhuber, 2017, DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci U S A, 114, 13076, 10.1073/pnas.1716483114 · DOI · Paper page
  18. Turnham, 2019, An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma, Elife, 8, e44187, 10.7554/eLife.44187 · DOI · Paper page
  19. Dinh, 2019, MicroRNA-375 suppresses the growth and invasion of fibrolamellar carcinoma, Cell Mol Gastroenterol Hepatol, 7, 803, 10.1016/j.jcmgh.2019.01.008 · DOI
  20. Graham, 2015, DNAJB1-PRKACA is specific for fibrolamellar carcinoma, Mod Pathol, 28, 822, 10.1038/modpathol.2015.4 · DOI · Paper page
  21. Turnham, 2016, Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology, Gene, 577, 101, 10.1016/j.gene.2015.11.052 · DOI · Paper page
  22. Riggle, 2016, Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma, Pediatr Res, 80, 110, 10.1038/pr.2016.36 · DOI · Paper page
  23. Cheung, 2015, Structural insights into mis-regulation of protein kinase A in human tumors, Proc Natl Acad Sci U S A, 112, 1374, 10.1073/pnas.1424206112 · DOI · Paper page
  24. Thatte, 2017, Kinase inhibitor demonstrates efficacy in a patient-derived xenograft model of fibrolamellar hepatocellular carcinoma featuring DNAJB1-PRKACA fusion, Cancer Res, 77, 4203, 10.1158/1538-7445.AM2017-4203 · doi:10.1158/1538-7445.am2017-4203
  25. Leinonen, 2017, Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours, Eur J Cancer, 77, 31, 10.1016/j.ejca.2017.02.017 · DOI · Paper page
  26. Davis, 2011, Comprehensive analysis of kinase inhibitor selectivity, Nat Biotechnol, 29, 1046, 10.1038/nbt.1990 · DOI · Paper page
  27. Oikawa, 2015, Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells, Nat Commun, 6, 8070, 10.1038/ncomms9070 · DOI
  28. Patro, 2017, Salmon provides fast and bias-aware quantification of transcript expression, Nat Methods, 14, 417, 10.1038/nmeth.4197 · DOI · Paper page
  29. Liberzon, 2015, The Molecular Signatures Database (MSigDB) hallmark gene set collection, Cell Syst, 1, 417, 10.1016/j.cels.2015.12.004 · DOI · Paper page
  30. Isobe, 2017, Systems-level identification of PKA-dependent signaling in epithelial cells, Proc Natl Acad Sci U S A, 114, E8875, 10.1073/pnas.1709123114 · DOI
  31. Dinh, 2020, Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal candidate oncogenic pathways and therapeutic vulnerabilities, Cell Rep, 31, 107509, 10.1016/j.celrep.2020.03.073 · DOI
  32. Spath, 1997, Hepatocyte nuclear factor 4 expression overcomes repression of the hepatic phenotype in dedifferentiated hepatoma cells, Mol Cell Biol, 17, 1913, 10.1128/MCB.17.4.1913 · DOI · Paper page
  33. Viollet, 1997, Protein kinase A-dependent phosphorylation modulates DNA-binding activity of hepatocyte nuclear factor 4, Mol Cell Biol, 17, 4208, 10.1128/MCB.17.8.4208 · DOI · Paper page
  34. Liu, 2009, cAMP enhances estrogen-related receptor alpha (ERRalpha) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2), Mol Endocrinol, 23, 772, 10.1210/me.2008-0282 · DOI
  35. Xia, 2019, ERRalpha as a bridge between transcription and function: role in liver metabolism and disease, Front Endocrinol (Lausanne), 10, 206, 10.3389/fendo.2019.00206 · DOI
  36. Cao, 2019, Structures of the PKA RIalpha holoenzyme with the FLHCC driver J-PKAcalpha or wild-type PKAcalpha, Structure, 27, 816, 10.1016/j.str.2019.03.001 · DOI · Paper page
  37. Lalazar, 2021, Identification of novel therapeutic targets for fibrolamellar carcinoma using patient derived xenografts and direct from patient screening, Cancer Discov, 11, 2544, 10.1158/2159-8290.CD-20-0872 · DOI
  38. Goh, 2014, Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors, Nat Genet, 46, 613, 10.1038/ng.2956 · DOI · Paper page
  39. Nakajima, 2014, Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication], Endocr J, 61, 825, 10.1507/endocrj.EJ14-0282 · DOI · Paper page
  40. Forlino, 2014, PRKACB and Carney complex, N Engl J Med, 370, 1065, 10.1056/NEJMc1309730 · DOI
  41. Yin, 2011, Differential role of PKA catalytic subunits in mediating phenotypes caused by knockout of the Carney complex gene Prkar1a, Mol Endocrinol, 25, 1786, 10.1210/me.2011-1008 · DOI
  42. Moody, 2015, PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling, Oncogene, 34, 2061, 10.1038/onc.2014.153 · DOI · Paper page
  43. Vyas, 2020, DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma, Mod Pathol, 33, 648, 10.1038/s41379-019-0398-2 · DOI · Paper page

Cited by

See all 14

Metadata

Authors
Schalm, S. S., O’Hearn, E., Wilson, K., LaBranche, T. P., Silva, G., Zhang, Z., DiPietro, L., Bifulco, N., Woessner, R., Stransky, N., Sappal, D., Campbell, R., Lobbardi, R., Palmer, M., Kim, J., Ye, C., Dorsch, M., Lengauer, C., Guzi, T., Kadambi, V., Garner, A., & Hoeflich, K. P.
Venue
Gastro Hep Advances
Publisher
Elsevier BV
Published
2023
Volume
2
Issue
3
Pages
307-321
ISSN
2772-5723
Cited by
14
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. https://app.cochat.ai/papers/10.1016/j.gastha.2022.11.004
The paper
Schalm, S. S., O’Hearn, E., Wilson, K., LaBranche, T. P., Silva, G., Zhang, Z., DiPietro, L., Bifulco, N., Woessner, R., Stransky, N., Sappal, D., Campbell, R., Lobbardi, R., Palmer, M., Kim, J., Ye, C., Dorsch, M., Lengauer, C., Guzi, T., . . . Hoeflich, K. P. (2023). Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. Gastro Hep Advances. https://doi.org/10.1016/j.gastha.2022.11.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.